Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per...
RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial...
Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in...
Trading under ticker symbol RADXComplements existing US shareholders (currently holding 21% of Radiopharm)No...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads